AXQ Capital LP Buys Shares of 6,824 Solventum Corporation $SOLV

AXQ Capital LP bought a new stake in Solventum Corporation (NYSE:SOLV) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,824 shares of the company’s stock, valued at approximately $541,000.

Several other institutional investors also recently modified their holdings of the business. Hilltop National Bank raised its stake in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in Solventum in the third quarter valued at approximately $25,000. JNBA Financial Advisors grew its holdings in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares during the period. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum during the 2nd quarter valued at $28,000. Finally, City State Bank raised its position in shares of Solventum by 166.7% during the 4th quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after acquiring an additional 240 shares during the last quarter.

Solventum Price Performance

SOLV opened at $78.39 on Thursday. The stock has a market cap of $13.58 billion, a P/E ratio of 9.61, a P/E/G ratio of 1.18 and a beta of 0.69. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a fifty day simple moving average of $70.21 and a 200 day simple moving average of $75.12.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SOLV shares. Rothschild & Co Redburn started coverage on Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wedbush assumed coverage on Solventum in a report on Friday, May 15th. They set an “outperform” rating and a $94.00 target price on the stock. Finally, KeyCorp boosted their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is owned by company insiders.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.